Complexity of immune responses to AAV transgene products – Example of factor IX

Cellular Immunology

Volumn 342, Issue , 2019, Pages

  Herzog, Roland W ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Adeno associated virus; Antibody; Gene therapy; Hemophilia; T cell; Tolerance

Indexed keywords

BLOOD CLOTTING FACTOR 9;

ADENO ASSOCIATED VIRUS; ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; GENE MUTATION; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IN VIVO GENE TRANSFER; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; RISK FACTOR; TRANSGENE; VIRAL GENE THERAPY; DEPENDOPARVOVIRUS; GENE THERAPY; GENE TRANSFER; GENETICS; HEMOPHILIA B; IMMUNOLOGY;

DEPENDOVIRUS; FACTOR IX; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HEMOPHILIA B; HUMANS; IMMUNE TOLERANCE; TRANSGENES;

EID: 85020938064     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2017.05.006     Document Type: Review

References (115)

1. Fisher, K.J., Jooss, K., Alston, J., Yang, Y., Haecker, S.E., High, K., Pathak, R., Raper, S.E., Wilson, J.M., Recombinant adeno-associated virus for muscle directed gene therapy. Nat. Med. 3 (1997), 306–312.
2. Kessler, P.D., Podsakoff, G.M., Chen, X., McQuiston, S.A., Colosi, P.C., Matelis, L.A., Kurtzman, G.J., Byrne, B.J., Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc. Natl. Acad. Sci. U.S.A. 93 (1996), 14082–14087.
3. Xiao, X., Li, J., Samulski, R.J., Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J. Virol. 70 (1996), 8098–8108.
4. Mays, L.E., Wilson, J.M., The complex and evolving story of T cell activation to AAV vector-encoded transgene products. Mol. Ther. 19 (2011), 16–27.
5. Calcedo, R., Somanathan, S., Qin, Q., Betts, M.R., Rech, A.J., Vonderheide, R.H., Mueller, C., Flotte, T.R., Wilson, J.M., Class I-restricted T-cell responses to a polymorphic peptide in a gene therapy clinical trial for alpha-1-antitrypsin deficiency. Proc. Natl. Acad. Sci. U.S.A. 114 (2017), 1655–1659.
6. Mendell, J.R., Campbell, K., Rodino-Klapac, L., Sahenk, Z., Shilling, C., Lewis, S., Bowles, D., Gray, S., Li, C., Galloway, G., Malik, V., Coley, B., Clark, K.R., Li, J., Xiao, X., Samulski, J., McPhee, S.W., Samulski, R.J., Walker, C.M., Dystrophin immunity in Duchenne's muscular dystrophy. N. Engl. J. Med. 363 (2010), 1429–1437.
7. Dolgin, E., Early clinical data raise the bar for hemophilia gene therapies. Nat. Biotechnol. 34 (2016), 999–1001.
8. Herzog, R.W., A cure for hemophilia: the promise becomes a reality. Mol. Ther. 24 (2016), 1503–1504.
9. Manno, C.S., Chew, A.J., Hutchison, S., Larson, P.J., Herzog, R.W., Arruda, V.R., Tai, S.J., Ragni, M.V., Thompson, A., Ozelo, M., Couto, L.B., Leonard, D.G., Johnson, F.A., McClelland, A., Scallan, C., Skarsgard, E., Flake, A.W., Kay, M.A., High, K.A., Glader, B., AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 101 (2003), 2963–2972.
10. Bennett, J., Ashtari, M., Wellman, J., Marshall, K.A., Cyckowski, L.L., Chung, D.C., McCague, S., Pierce, E.A., Chen, Y., Bennicelli, J.L., Zhu, X., Ying, G.S., Sun, J., Wright, J.F., Auricchio, A., Simonelli, F., Shindler, K.S., Mingozzi, F., High, K.A., Maguire, A.M., AAV2 gene therapy readministration in three adults with congenital blindness. Sci. Transl. Med., 4, 2012, 120ra115.
11. Bennett, J., Wellman, J., Marshall, K.A., McCague, S., Ashtari, M., DiStefano-Pappas, J., Elci, O.U., Chung, D.C., Sun, J., Wright, J.F., Cross, D.R., Aravand, P., Cyckowski, L.L., Bennicelli, J.L., Mingozzi, F., Auricchio, A., Pierce, E.A., Ruggiero, J., Leroy, B.P., Simonelli, F., High, K.A., Maguire, A.M., Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial. Lancet 388 (2016), 661–672.
12. Kumar, S.R., Markusic, D.M., Biswas, M., High, K.A., Herzog, R.W., Clinical development of gene therapy: results and lessons from recent successes. Mol. Ther. Methods Clin. Dev., 3, 2016, 16034.
13. Mingozzi, F., High, K.A., Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 122 (2013), 23–36.
14. Rogers, G.L., Herzog, R.W., Gene therapy for hemophilia. Front. Biosci. (Landmark Ed) 20 (2015), 556–603.
15. Nienhuis, A.W., Nathwani, A.C., Davidoff, A.M., Gene therapy for hemophilia. Mol. Ther. 25 (2017), 1163–1167.
16. Batsuli, G., Meeks, S.L., Herzog, R.W., Lacroix-Desmazes, S., Innovating immune tolerance induction for haemophilia. Haemophilia 22:Suppl 5 (2016), 31–35.
17. Scott, D.W., Pratt, K.P., Miao, C.H., Progress toward inducing immunologic tolerance to factor VIII. Blood 121 (2013), 4449–4456.
18. Srivastava, A., In vivo tissue-tropism of adeno-associated viral vectors. Curr. Opin. Virol. 21 (2016), 75–80.
19. Kay, M.A., Manno, C.S., Ragni, M.V., Larson, P.J., Couto, L.B., McClelland, A., Glader, B., Chew, A.J., Tai, S.J., Herzog, R.W., Arruda, V., Johnson, F., Scallan, C., Skarsgard, E., Flake, A.W., High, K.A., Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat. Genet. 24 (2000), 257–261.
20. Nichols, T.C., Whitford, M.H., Arruda, V.R., Stedman, H.H., Kay, M.A., High, K.A., Translational data from adeno-associated virus-mediated gene therapy of hemophilia B in dogs. Hum. Gene Ther. Clin. Dev. 26 (2015), 5–14.
21. Fields, P.A., Kowalczyk, D.W., Arruda, V.R., Armstrong, E., McCleland, M.L., Hagstrom, J.N., Pasi, K.J., Ertl, H.C., Herzog, R.W., High, K.A., Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX. Mol. Ther. 1 (2000), 225–235.
22. Jooss, K., Yang, Y., Fisher, K.J., Wilson, J.M., Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J. Virol. 72 (1998), 4212–4223.
23. Sun, B., Zhang, H., Franco, L.M., Brown, T., Bird, A., Schneider, A., Koeberl, D.D., Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter. Mol. Ther. 11 (2005), 889–898.
24. Majowicz, A., Maczuga, P., Kwikkers, K.L., van der Marel, S., van Logtenstein, R., Petry, H., van Deventer, S.J., Konstantinova, P., Ferreira, V., Mir-142-3p target sequences reduce transgene-directed immunogenicity following intramuscular adeno-associated virus 1 vector-mediated gene delivery. J. Gene Med. 15 (2013), 219–232.
25. Sarukhan, A., Soudais, C., Danos, O., Jooss, K., Factors influencing cross-presentation of non-self antigens expressed from recombinant adeno-associated virus vectors. J. Gene Med. 3 (2001), 260–270.
26. Wang, L., Dobrzynski, E., Schlachterman, A., Cao, O., Herzog, R.W., Systemic protein delivery by muscle-gene transfer is limited by a local immune response. Blood 105 (2005), 4226–4234.
27. Xu, D., Walker, C.M., Continuous CD8(+) T-cell priming by dendritic cell cross-presentation of persistent antigen following adeno-associated virus-mediated gene delivery. J. Virol. 85 (2011), 12083–12086.
28. Cao, O., Hoffman, B.E., Moghimi, B., Nayak, S., Cooper, M., Zhou, S., Ertl, H.C., High, K.A., Herzog, R.W., Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B. Mol. Ther. 17 (2009), 1733–1742.
29. Hoffman, B.E., Dobrzynski, E., Wang, L., Hirao, L., Mingozzi, F., Cao, O., Herzog, R.W., Muscle as a target for supplementary factor IX gene transfer. Human Gene Ther. 18 (2007), 603–613.
30. Rogers, G.L., Martino, A.T., Zolotukhin, I., Ertl, H.C., Herzog, R.W., Role of the vector genome and underlying factor IX mutation in immune responses to AAV gene therapy for hemophilia B. J. Transl. Med., 12, 2014, 25.
31. Wang, L., Cao, O., Swalm, B., Dobrzynski, E., Mingozzi, F., Herzog, R.W., Major role of local immune responses in antibody formation to factor IX in AAV gene transfer. Gene Ther. 12 (2005), 1453–1464.
32. Boisgerault, F., Mingozzi, F., The skeletal muscle environment and its role in immunity and tolerance to AAV vector-mediated gene transfer. Curr. Gene Ther. 15 (2015), 381–394.
33. Lin, S.W., Hensley, S.E., Tatsis, N., Lasaro, M.O., Ertl, H.C., Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice. J. Clin. Invest. 117 (2007), 3958–3970.
34. Velazquez, V.M., Bowen, D.G., Walker, C.M., Silencing of T lymphocytes by antigen-driven programmed death in recombinant adeno-associated virus vector-mediated gene therapy. Blood 113 (2009), 538–545.
35. Wu, T., Topfer, K., Lin, S.W., Li, H., Bian, A., Zhou, X.Y., High, K.A., Ertl, H.C., Self-complementary AAVs induce more potent transgene product-specific immune responses compared to a single-stranded genome. Mol. Ther. 20 (2012), 572–579.
36. Faust, S.M., Bell, P., Cutler, B.J., Ashley, S.N., Zhu, Y., Rabinowitz, J.E., Wilson, J.M., CpG-depleted adeno-associated virus vectors evade immune detection. J. Clin. Invest. 123 (2013), 2994–3001.
37. Rogers, G.L., Suzuki, M., Zolotukhin, I., Markusic, D.M., Morel, L.M., Lee, B., Ertl, H.C., Herzog, R.W., Unique roles of TLR9- and MyD88-dependent and -independent pathways in adaptive immune responses to AAV-mediated gene transfer. J. Innate Immun. 7 (2015), 302–314.
38. Martino, A.T., Suzuki, M., Markusic, D.M., Zolotukhin, I., Ryals, R.C., Moghimi, B., Ertl, H.C., Muruve, D.A., Lee, B., Herzog, R.W., The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver. Blood 117 (2011), 6459–6468.
39. Sudres, M., Cire, S., Vasseur, V., Brault, L., Da Rocha, S., Boisgerault, F., Le Bec, C., Gross, D.A., Blouin, V., Ryffel, B., Galy, A., MyD88 signaling in B cells regulates the production of Th1-dependent antibodies to AAV. Mol. Ther. 20 (2012), 1571–1581.
40. Fields, P.A., Arruda, V.R., Armstrong, E., Chu, K., Mingozzi, F., Hagstrom, J.N., Herzog, R.W., High, K.A., Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9. Mol. Ther. 4 (2001), 201–210.
41. Herzog, R.W., Fields, P.A., Arruda, V.R., Brubaker, J.O., Armstrong, E., McClintock, D., Bellinger, D.A., Couto, L.B., Nichols, T.C., High, K.A., Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy. Human Gene Ther. 13 (2002), 1281–1291.
42. Herzog, R.W., Mount, J.D., Arruda, V.R., High, K.A., Lothrop, C.D. Jr., Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation. Mol. Ther. 4 (2001), 192–200.
43. Arruda, V.R., Schuettrumpf, J., Herzog, R.W., Nichols, T.C., Robinson, N., Lotfi, Y., Mingozzi, F., Xiao, W., Couto, L.B., High, K.A., Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1. Blood 103 (2004), 85–92.
44. Gernoux, G., Guilbaud, M., Dubreil, L., Larcher, T., Babarit, C., Ledevin, M., Jaulin, N., Planel, P., Moullier, P., Adjali, O., Early interaction of adeno-associated virus serotype 8 vector with the host immune system following intramuscular delivery results in weak but detectable lymphocyte and dendritic cell transduction. Human Gene Ther. 26 (2015), 1–13.
45. Lu, Y., Song, S., Distinct immune responses to transgene products from rAAV1 and rAAV8 vectors. Proc. Natl. Acad. Sci. U.S.A. 106 (2009), 17158–17162.
46. Arruda, V.R., Stedman, H.H., Nichols, T.C., Haskins, M.E., Nicholson, M., Herzog, R.W., Couto, L.B., High, K.A., Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model. Blood 105 (2005), 3458–3464.
47. Arruda, V.R., Stedman, H.H., Haurigot, V., Buchlis, G., Baila, S., Favaro, P., Chen, Y., Franck, H.G., Zhou, S., Wright, J.F., Couto, L.B., Jiang, H., Pierce, G.F., Bellinger, D.A., Mingozzi, F., Nichols, T.C., High, K.A., Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B. Blood 115 (2010), 4678–4688.
48. Mueller, C., Chulay, J.D., Trapnell, B.C., Humphries, M., Carey, B., Sandhaus, R.A., McElvaney, N.G., Messina, L., Tang, Q., Rouhani, F.N., Campbell-Thompson, M., Fu, A.D., Yachnis, A., Knop, D.R., Ye, G.J., Brantly, M., Calcedo, R., Somanathan, S., Richman, L.P., Vonderheide, R.H., Hulme, M.A., Brusko, T.M., Wilson, J.M., Flotte, T.R., Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression. J. Clin. Invest. 123 (2013), 5310–5318.
49. Sarkar, D., Biswas, M., Liao, G., Seay, H.R., Perrin, G.Q., Markusic, D.M., Hoffman, B.E., Brusko, T.M., Terhorst, C., Herzog, R.W., Ex vivo expanded autologous polyclonal regulatory T cells suppress inhibitor formation in hemophilia. Mol. Ther. Methods Clin. Dev., 1, 2014, 14030.
50. Kim, Y.C., Zhang, A.H., Su, Y., Rieder, S.A., Rossi, R.J., Ettinger, R.A., Pratt, K.P., Shevach, E.M., Scott, D.W., Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T- and B-cell responses. Blood 125 (2015), 1107–1115.
51. Yoon, J., Schmidt, A., Zhang, A.H., Konigs, C., Kim, Y.C., Scott, D.W., FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII. Blood 129 (2017), 238–245.
52. Miao, C.H., Tilt balance towards regulation: evolving new strategy for treatment of hemophilia inhibitors. J. Thromb. Haemost. 9 (2011), 1521–1523.
53. Biswas, M., Sarkar, D., Kumar, S.R., Nayak, S., Rogers, G.L., Markusic, D.M., Liao, G., Terhorst, C., Herzog, R.W., Synergy between rapamycin and FLT3 ligand enhances plasmacytoid dendritic cell-dependent induction of CD4+CD25+FoxP3+ Treg. Blood 125 (2015), 2937–2947.
54. Nayak, S., Cao, O., Hoffman, B.E., Cooper, M., Zhou, S., Atkinson, M.A., Herzog, R.W., Prophylactic immune tolerance induced by changing the ratio of antigen-specific effector to regulatory T cells. J. Thromb. Haemost. 7 (2009), 1523–1532.
55. Nayak, S., Sarkar, D., Perrin, G.Q., Moghimi, B., Hoffman, B.E., Zhou, S., Byrne, B.J., Herzog, R.W., Prevention and reversal of antibody responses against factor IX in gene therapy for hemophilia B. Front. Microbiol., 2, 2011, 244.
56. Swee, L.K., Bosco, N., Malissen, B., Ceredig, R., Rolink, A., Expansion of peripheral naturally occurring T regulatory cells by Fms-like tyrosine kinase 3 ligand treatment. Blood 113 (2009), 6277–6287.
57. Agudo, J., Ruzo, A., Tung, N., Salmon, H., Leboeuf, M., Hashimoto, D., Becker, C., Garrett-Sinha, L.A., Baccarini, A., Merad, M., Brown, B.D., The miR-126-VEGFR2 axis controls the innate response to pathogen-associated nucleic acids. Nat. Immunol. 15 (2014), 54–62.
58. Chen, W., Liang, X., Peterson, A.J., Munn, D.H., Blazar, B.R., The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J. Immunol. 181 (2008), 5396–5404.
59. Maldonado, R.A., LaMothe, R.A., Ferrari, J.D., Zhang, A.H., Rossi, R.J., Kolte, P.N., Griset, A.P., O'Neil, C., Altreuter, D.H., Browning, E., Johnston, L., Farokhzad, O.C., Langer, R., Scott, D.W., von Andrian, U.H., Kishimoto, T.K., Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance. Proc. Natl. Acad. Sci. U.S.A. 112 (2015), E156–165.
60. Zhang, A.H., Rossi, R.J., Yoon, J., Wang, H., Scott, D.W., Tolerogenic nanoparticles to induce immunologic tolerance: Prevention and reversal of FVIII inhibitor formation. Cell. Immunol. 301 (2016), 74–81.
61. Hardet, R., Chevalier, B., Dupaty, L., Naimi, Y., Riou, G., Drouot, L., Jean, L., Salvetti, A., Boyer, O., Adriouch, S., Oral-tolerization prevents immune responses and improves transgene persistence following gene transfer mediated by adeno-associated viral vector. Mol. Ther. 24 (2016), 87–95.
62. Wang, X., Sherman, A., Liao, G., Leong, K.W., Daniell, H., Terhorst, C., Herzog, R.W., Mechanism of oral tolerance induction to therapeutic proteins. Adv. Drug Deliv. Rev. 65 (2013), 759–773.
63. Wang, X., Su, J., Sherman, A., Rogers, G.L., Liao, G., Hoffman, B.E., Leong, K.W., Terhorst, C., Daniell, H., Herzog, R.W., Plant-based oral tolerance to hemophilia therapy employs a complex immune regulatory response including LAP+CD4+ T cells. Blood 125 (2015), 2418–2427.
64. Wang, X., Terhorst, C., Herzog, R.W., In vivo induction of regulatory T cells for immune tolerance in hemophilia. Cell. Immunol. 301 (2016), 18–29.
65. Hardet, R., Mingozzi, F., Oral tolerance: another reason to eat your veggies!. Mol. Ther. 25 (2017), 311–313.
66. Herzog, R.W., Nichols, T.C., Su, J., Zhang, B., Sherman, A., Merricks, E.P., Raymer, R., Perrin, G.Q., Hager, M., Wiinberg, B., Daniell, H., Oral tolerance induction in hemophilia B dogs fed with transplastomic lettuce. Mol. Ther. 25 (2017), 512–522.
67. Mingozzi, F., Liu, Y.L., Dobrzynski, E., Kaufhold, A., Liu, J.H., Wang, Y., Arruda, V.R., High, K.A., Herzog, R.W., Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J. Clin Invest. 111 (2003), 1347–1356.
68. LoDuca, P.A., Hoffman, B.E., Herzog, R.W., Hepatic gene transfer as a means of tolerance induction to transgene products. Curr. Gene Ther. 9 (2009), 104–114.
69. Mak, K.Y., Rajapaksha, I.G., Angus, P.W., Herath, C.B., The adeno-associated virus – a safe and effective vehicle for liver-specific gene therapy of inherited and non-inherited diseases. Curr. Gene Ther., 2017.
70. Sack, B.K., Herzog, R.W., Terhorst, C., Markusic, D.M., Development of gene transfer for induction of antigen-specific tolerance. Mol. Ther. Methods Clin. Dev., 1, 2014, 14013.
71. Crudele, J.M., Finn, J.D., Siner, J.I., Martin, N.B., Niemeyer, G.P., Zhou, S., Mingozzi, F., Lothrop, C.D. Jr., Arruda, V.R., AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice. Blood 125 (2015), 1553–1561.
72. Mingozzi, F., Hasbrouck, N.C., Basner-Tschakarjan, E., Edmonson, S.A., Hui, D.J., Sabatino, D.E., Zhou, S., Wright, J.F., Jiang, H., Pierce, G.F., Arruda, V.R., High, K.A., Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. Blood 110 (2007), 2334–2341.
73. Niemeyer, G.P., Herzog, R.W., Mount, J., Arruda, V.R., Tillson, D.M., Hathcock, J., van Ginkel, F.W., High, K.A., Lothrop, C.D. Jr., Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. Blood 113 (2009), 797–806.
74. Nietupski, J.B., Hurlbut, G.D., Ziegler, R.J., Chu, Q., Hodges, B.L., Ashe, K.M., Bree, M., Cheng, S.H., Gregory, R.J., Marshall, J., Scheule, R.K., Systemic administration of AAV8-alpha-galactosidase A induces humoral tolerance in nonhuman primates despite low hepatic expression. Mol. Ther. 19 (2011), 1999–2011.
75. Manno, C.S., Pierce, G.F., Arruda, V.R., Glader, B., Ragni, M., Rasko, J.J., Ozelo, M.C., Hoots, K., Blatt, P., Konkle, B., Dake, M., Kaye, R., Razavi, M., Zajko, A., Zehnder, J., Rustagi, P.K., Nakai, H., Chew, A., Leonard, D., Wright, J.F., Lessard, R.R., Sommer, J.M., Tigges, M., Sabatino, D., Luk, A., Jiang, H., Mingozzi, F., Couto, L., Ertl, H.C., High, K.A., Kay, M.A., Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 12 (2006), 342–347.
76. Nathwani, A.C., Reiss, U.M., Tuddenham, E.G., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., Riddell, A., Pie, J., Rangarajan, S., Bevan, D., Recht, M., Shen, Y.M., Halka, K.G., Basner-Tschakarjan, E., Mingozzi, F., High, K.A., Allay, J., Kay, M.A., Ng, C.Y., Zhou, J., Cancio, M., Morton, C.L., Gray, J.T., Srivastava, D., Nienhuis, A.W., Davidoff, A.M., Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N. Engl. J. Med. 371 (2014), 1994–2004.
77. Nathwani, A.C., Rosales, C., McIntosh, J., Rastegarlari, G., Nathwani, D., Raj, D., Nawathe, S., Waddington, S.N., Bronson, R., Jackson, S., Donahue, R.E., High, K.A., Mingozzi, F., Ng, C.Y., Zhou, J., Spence, Y., McCarville, M.B., Valentine, M., Allay, J., Coleman, J., Sleep, S., Gray, J.T., Nienhuis, A.W., Davidoff, A.M., Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Mol. Ther. 19 (2011), 876–885.
78. Nienhuis, A.W., Nathwani, A.C., Davidoff, A.M., Gene therapy for hemophilia. Mol. Ther., 2017.
79. Thomson, A.W., Knolle, P.A., Antigen-presenting cell function in the tolerogenic liver environment. Nat. Rev. Immunol. 10 (2010), 753–766.
80. Perrin, G.Q., Zolotukhin, I., Sherman, A., Biswas, M., de Jong, Y.P., Terhorst, C., Davidoff, A.M., Herzog, R.W., Dynamics of antigen presentation to transgene product-specific CD4+ T cells and of Treg induction upon hepatic AAV gene transfer. Mol. Ther. Methods Clin. Dev., 3, 2016, 16083.
81. Hoffman, B.E., Martino, A.T., Sack, B.K., Cao, O., Liao, G., Terhorst, C., Herzog, R.W., Nonredundant roles of IL-10 and TGF-beta in suppression of immune responses to hepatic AAV-factor IX gene transfer. Mol. Ther. 19 (2011), 1263–1272.
82. Cooper, M., Nayak, S., Hoffman, B.E., Terhorst, C., Cao, O., Herzog, R.W., Improved induction of immune tolerance to factor IX by hepatic AAV-8 gene transfer. Human Gene Ther. 20 (2009), 767–776.
83. Markusic, D.M., Hoffman, B.E., Perrin, G.Q., Nayak, S., Wang, X., LoDuca, P.A., High, K.A., Herzog, R.W., Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies. EMBO Mol. Med. 5 (2013), 1698–1709.
84. Sack, B.K., Merchant, S., Markusic, D.M., Nathwani, A.C., Davidoff, A.M., Byrne, B.J., Herzog, R.W., Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy. PloS One, 7, 2012, e37671.
85. Dobrzynski, E., Mingozzi, F., Liu, Y.L., Bendo, E., Cao, O., Wang, L., Herzog, R.W., Induction of antigen-specific CD4+ T-cell anergy and deletion by in vivo viral gene transfer. Blood 104 (2004), 969–977.
86. Faust, S.M., Bell, P., Zhu, Y., Sanmiguel, J., Wilson, J.M., The role of apoptosis in immune hyporesponsiveness following AAV8 liver gene transfer. Mol. Ther. 21 (2013), 2227–2235.
87. Cao, O., Dobrzynski, E., Wang, L., Nayak, S., Mingle, B., Terhorst, C., Herzog, R.W., Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer. Blood 110 (2007), 1132–1140.
88. Dobrzynski, E., Fitzgerald, J.C., Cao, O., Mingozzi, F., Wang, L., Herzog, R.W., Prevention of cytotoxic T lymphocyte responses to factor IX-expressing hepatocytes by gene transfer-induced regulatory T cells. Proc. Natl. Acad. Sci. U.S.A. 103 (2006), 4592–4597.
89. Doerfler, P.A., Todd, A.G., Clement, N., Falk, D.J., Nayak, S., Herzog, R.W., Byrne, B.J., Copackaged AAV9 vectors promote simultaneous immune tolerance and phenotypic correction of pompe disease. Human Gene Ther. 27 (2016), 43–59.
90. Breous, E., Somanathan, S., Vandenberghe, L.H., Wilson, J.M., Hepatic regulatory T cells and Kupffer cells are crucial mediators of systemic T cell tolerance to antigens targeting murine liver. Hepatology 50 (2009), 612–621.
91. Xu, L., Yin, W., Sun, R., Wei, H., Tian, Z., Liver type I regulatory T cells suppress germinal center formation in HBV-tolerant mice. Proc. Natl. Acad. Sci. U.S.A. 110 (2013), 16993–16998.
92. Annoni, A., Cantore, A., Della Valle, P., Goudy, K., Akbarpour, M., Russo, F., Bartolaccini, S., D'Angelo, A., Roncarolo, M.G., Naldini, L., Liver gene therapy by lentiviral vectors reverses anti-factor IX pre-existing immunity in haemophilic mice. EMBO Mol. Med. 5 (2013), 1684–1697.
93. Finn, J.D., Ozelo, M.C., Sabatino, D.E., Franck, H.W., Merricks, E.P., Crudele, J.M., Zhou, S., Kazazian, H.H., Lillicrap, D., Nichols, T.C., Arruda, V.R., Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy. Blood 116 (2010), 5842–5848.
94. Finn, J.D., Nichols, T.C., Svoronos, N., Merricks, E.P., Bellenger, D.A., Zhou, S., Simioni, P., High, K.A., Arruda, V.R., The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy. Blood 120 (2012), 4521–4523.
95. Lytle, A.M., Brown, H.C., Paik, N.Y., Knight, K.A., Wright, J.F., Spencer, H.T., Doering, C.B., Effects of FVIII immunity on hepatocyte and hematopoietic stem cell-directed gene therapy of murine hemophilia A. Mol. Ther. Methods Clin. Dev., 3, 2016, 15056.
96. Zolotukhin, I., Markusic, D.M., Palaschak, B., Hoffman, B.E., Srikanthan, M.A., Herzog, R.W., Potential for cellular stress response to hepatic factor VIII expression from AAV vector. Mol. Ther. Methods Clin. Dev., 3, 2016, 16063.
97. Lange, A.M., Altynova, E.S., Nguyen, G.N., Sabatino, D.E., Overexpression of factor VIII after AAV delivery is transiently associated with cellular stress in hemophilia A mice. Mol. Ther. Methods Clin. Dev., 3, 2016, 16064.
98. Biswas, M., Rogers, G.L., Sherman, A., Byrne, B.J., Markusic, D.M., Jiang, H., Herzog, R.W., Combination therapy for inhibitor reversal in haemophilia A using monoclonal anti-CD20 and rapamycin. Thromb. Haemost. 117 (2017), 33–43.
99. Corti, M., Elder, M., Falk, D., Lawson, L., Smith, B., Nayak, S., Conlon, T., Clement, N., Erger, K., Lavassani, E., Green, M., Doerfler, P., Herzog, R., Byrne, B., B-cell depletion is protective against anti-AAV capsid immune response: a human subject case study. Mol. Ther. Methods Clin. Dev., 1, 2014.
100. Doerfler, P.A., Nayak, S., Corti, M., Morel, L., Herzog, R.W., Byrne, B.J., Targeted approaches to induce immune tolerance for Pompe disease therapy. Mol. Ther. Methods Clin. Dev., 3, 2016, 15053.
101. Elder, M.E., Nayak, S., Collins, S.W., Lawson, L.A., Kelley, J.S., Herzog, R.W., Modica, R.F., Lew, J., Lawrence, R.M., Byrne, B.J., B-Cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset Pompe disease. J. Pediatr. 163 (2013), 847–854 e841.
102. Han, S.O., Ronzitti, G., Arnson, B., Leborgne, C., Li, S., Mingozzi, F., Koeberl, D., Low-dose liver-targeted gene therapy for pompe disease enhances therapeutic efficacy of ERT via immune tolerance induction. Mol. Ther. Methods Clin. Dev. 4 (2017), 126–136.
103. Passini, M.A., Bu, J., Fidler, J.A., Ziegler, R.J., Foley, J.W., Dodge, J.C., Yang, W.W., Clarke, J., Taksir, T.V., Griffiths, D.A., Zhao, M.A., O'Riordan, C.R., Schuchman, E.H., Shihabuddin, L.S., Cheng, S.H., Combination brain and systemic injections of AAV provide maximal functional and survival benefits in the Niemann-Pick mouse. Proc. Natl. Acad. Sci. U.S.A. 104 (2007), 9505–9510.
104. Zhang, P., Sun, B., Osada, T., Rodriguiz, R., Yang, X.Y., Luo, X., Kemper, A.R., Clay, T.M., Koeberl, D.D., Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine pompe disease. Human Gene Ther. 23 (2012), 460–472.
105. Akbarpour, M., Goudy, K.S., Cantore, A., Russo, F., Sanvito, F., Naldini, L., Annoni, A., Roncarolo, M.G., Insulin B chain 9–23 gene transfer to hepatocytes protects from type 1 diabetes by inducing Ag-specific FoxP3+ Tregs. Sci. Transl. Med., 7, 2015, 289ra281.
106. Chan, C.C., Lai, C.W., Wu, C.J., Chen, L.C., Tao, M.H., Kuo, M.L., Liver-specific allergen gene transfer by adeno-associated virus suppresses allergic airway inflammation in mice. Human Gene Ther. 27 (2016), 631–642.
107. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner-Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., de Jong, Y.P., Herzog, R.W., Superior in vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24 (2016), 1042–1049.
108. Kumar, S.R., Hoffman, B.E., Terhorst, C., de Jong, Y.P., Herzog, R.W., The balance between CD8+ T cell-mediated clearance of AAV-encoded antigen in the liver and tolerance is dependent on the vector dose. Mol. Ther. 25 (2017), 880–891.
109. Nathwani, A.C., Gray, J.T., Ng, C.Y., Zhou, J., Spence, Y., Waddington, S.N., Tuddenham, E.G., Kemball-Cook, G., McIntosh, J., Boon-Spijker, M., Mertens, K., Davidoff, A.M., Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood 107 (2006), 2653–2661.
110. Fuchs, S.P., Desrosiers, R.C., Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies. Mol. Ther. Methods Clin. Dev., 3, 2016, 16068.
111. Flanigan, K.M., Campbell, K., Viollet, L., Wang, W., Gomez, A.M., Walker, C.M., Mendell, J.R., Anti-dystrophin T cell responses in Duchenne muscular dystrophy: prevalence and a glucocorticoid treatment effect. Human Gene Ther. 24 (2013), 797–806.
112. Viel, K.R., Ameri, A., Abshire, T.C., Iyer, R.V., Watts, R.G., Lutcher, C., Channell, C., Cole, S.A., Fernstrom, K.M., Nakaya, S., Kasper, C.K., Thompson, A.R., Almasy, L., Howard, T.E., Inhibitors of factor VIII in black patients with hemophilia. N. Engl. J. Med. 360 (2009), 1618–1627.
113. Gunasekera, D., Ettinger, R.A., Nakaya Fletcher, S., James, E.A., Liu, M., Barrett, J.C., Withycombe, J., Matthews, D.C., Epstein, M.S., Hughes, R.J., Pratt, K.P., I. Personalized approaches to therapies for hemophilia study, Factor VIII gene variants and inhibitor risk in African American hemophilia A patients. Blood 126 (2015), 895–904.
114. Corti, M., Cleaver, B., Clement, N., Conlon, T.J., Faris, K.J., Wang, G., Benson, J., Tarantal, A.F., Fuller, D., Herzog, R.W., Byrne, B.J., Evaluation of readministration of a recombinant adeno-associated virus vector expressing acid alpha-glucosidase in pompe disease: preclinical to clinical planning. Hum. Gene Ther. Clin. Dev. 26 (2015), 185–193.
115. Basner-Tschakarjan, E., Mingozzi, F., Cell-mediated immunity to AAV vectors evolving concepts and potential solutions. Front. Immunol., 5, 2014, 350.